Global Neurodegenerative Disorder Therapeutics Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI09242453

Publication Date:

September 23, 2024

Pages:

132

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Neurodegenerative Disorder Therapeutics market size was valued at US$ million in 2023. With growing demand in downstream market, the Neurodegenerative Disorder Therapeutics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Neurodegenerative Disorder Therapeutics market. Neurodegenerative Disorder Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurodegenerative Disorder Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurodegenerative Disorder Therapeutics market.
The goal of听therapeutic听development for听neurodegenerative听disorders听is to develop drugs that slow down or stop the听neurodegenerative听process. So-called neuroprotective, or听disease-modifying,听therapies听would not only treat the symptoms but slow the continued loss of neurons in听disease.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Neurodegenerative Disorder Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurodegenerative Disorder Therapeutics market. It may include historical data, market segmentation by Type (e.g., Immunomodulators, Interferons), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurodegenerative Disorder Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurodegenerative Disorder Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurodegenerative Disorder Therapeutics industry. This include advancements in Neurodegenerative Disorder Therapeutics technology, Neurodegenerative Disorder Therapeutics new entrants, Neurodegenerative Disorder Therapeutics new investment, and other innovations that are shaping the future of Neurodegenerative Disorder Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurodegenerative Disorder Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Neurodegenerative Disorder Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurodegenerative Disorder Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurodegenerative Disorder Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurodegenerative Disorder Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurodegenerative Disorder Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurodegenerative Disorder Therapeutics market.
Market Segmentation:
Neurodegenerative Disorder Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
Segmentation by application
Multiple Sclerosis
Parkinson'S Disease
Alzheimer'S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen, Inc.
Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co., Ltd

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurodegenerative Disorder Therapeutics Market Size 2019-2030
2.1.2 Neurodegenerative Disorder Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neurodegenerative Disorder Therapeutics Segment by Type
2.2.1 Immunomodulators
2.2.2 Interferons
2.2.3 Decarboxylase Inhibitors
2.2.4 Dopamine Agonists
2.2.5 Others
2.3 Neurodegenerative Disorder Therapeutics Market Size by Type
2.3.1 Neurodegenerative Disorder Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neurodegenerative Disorder Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Neurodegenerative Disorder Therapeutics Segment by Application
2.4.1 Multiple Sclerosis
2.4.2 Parkinson'S Disease
2.4.3 Alzheimer'S Disease
2.4.4 Spinal Muscular Atrophy
2.4.5 Huntington Disease
2.4.6 Other Neurodegenerative Disorders
2.5 Neurodegenerative Disorder Therapeutics Market Size by Application
2.5.1 Neurodegenerative Disorder Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neurodegenerative Disorder Therapeutics Market Size Market Share by Application (2019-2024)
3 Neurodegenerative Disorder Therapeutics Market Size by Player
3.1 Neurodegenerative Disorder Therapeutics Market Size Market Share by Players
3.1.1 Global Neurodegenerative Disorder Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Disorder Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Neurodegenerative Disorder Therapeutics by Regions
4.1 Neurodegenerative Disorder Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Neurodegenerative Disorder Therapeutics Market Size Growth (2019-2024)
4.3 APAC Neurodegenerative Disorder Therapeutics Market Size Growth (2019-2024)
4.4 Europe Neurodegenerative Disorder Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
5.2 Americas Neurodegenerative Disorder Therapeutics Market Size by Type (2019-2024)
5.3 Americas Neurodegenerative Disorder Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurodegenerative Disorder Therapeutics Market Size by Region (2019-2024)
6.2 APAC Neurodegenerative Disorder Therapeutics Market Size by Type (2019-2024)
6.3 APAC Neurodegenerative Disorder Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neurodegenerative Disorder Therapeutics by Country (2019-2024)
7.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2019-2024)
7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurodegenerative Disorder Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Neurodegenerative Disorder Therapeutics Market Forecast
10.1 Global Neurodegenerative Disorder Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Neurodegenerative Disorder Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Neurodegenerative Disorder Therapeutics Forecast
10.1.3 APAC Neurodegenerative Disorder Therapeutics Forecast
10.1.4 Europe Neurodegenerative Disorder Therapeutics Forecast
10.1.5 Middle East & Africa Neurodegenerative Disorder Therapeutics Forecast
10.2 Americas Neurodegenerative Disorder Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Neurodegenerative Disorder Therapeutics Market Forecast
10.2.2 Canada Neurodegenerative Disorder Therapeutics Market Forecast
10.2.3 Mexico Neurodegenerative Disorder Therapeutics Market Forecast
10.2.4 Brazil Neurodegenerative Disorder Therapeutics Market Forecast
10.3 APAC Neurodegenerative Disorder Therapeutics Forecast by Region (2025-2030)
10.3.1 China Neurodegenerative Disorder Therapeutics Market Forecast
10.3.2 Japan Neurodegenerative Disorder Therapeutics Market Forecast
10.3.3 Korea Neurodegenerative Disorder Therapeutics Market Forecast
10.3.4 Southeast Asia Neurodegenerative Disorder Therapeutics Market Forecast
10.3.5 India Neurodegenerative Disorder Therapeutics Market Forecast
10.3.6 Australia Neurodegenerative Disorder Therapeutics Market Forecast
10.4 Europe Neurodegenerative Disorder Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Neurodegenerative Disorder Therapeutics Market Forecast
10.4.2 France Neurodegenerative Disorder Therapeutics Market Forecast
10.4.3 UK Neurodegenerative Disorder Therapeutics Market Forecast
10.4.4 Italy Neurodegenerative Disorder Therapeutics Market Forecast
10.4.5 Russia Neurodegenerative Disorder Therapeutics Market Forecast
10.5 Middle East & Africa Neurodegenerative Disorder Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Neurodegenerative Disorder Therapeutics Market Forecast
10.5.2 South Africa Neurodegenerative Disorder Therapeutics Market Forecast
10.5.3 Israel Neurodegenerative Disorder Therapeutics Market Forecast
10.5.4 Turkey Neurodegenerative Disorder Therapeutics Market Forecast
10.5.5 GCC Countries Neurodegenerative Disorder Therapeutics Market Forecast
10.6 Global Neurodegenerative Disorder Therapeutics Forecast by Type (2025-2030)
10.7 Global Neurodegenerative Disorder Therapeutics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Biogen, Inc.
11.1.1 Biogen, Inc. Company Information
11.1.2 Biogen, Inc. Neurodegenerative Disorder Therapeutics Product Offered
11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Biogen, Inc. Main Business Overview
11.1.5 Biogen, Inc. Latest Developments
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Information
11.2.2 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product Offered
11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Pfizer, Inc. Main Business Overview
11.2.5 Pfizer, Inc. Latest Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Information
11.3.2 Novartis AG Neurodegenerative Disorder Therapeutics Product Offered
11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Novartis AG Main Business Overview
11.3.5 Novartis AG Latest Developments
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Information
11.4.2 Sanofi S.A. Neurodegenerative Disorder Therapeutics Product Offered
11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Sanofi S.A. Main Business Overview
11.4.5 Sanofi S.A. Latest Developments
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Information
11.5.2 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product Offered
11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.5.5 Teva Pharmaceutical Industries Ltd. Latest Developments
11.6 UCB S.A.
11.6.1 UCB S.A. Company Information
11.6.2 UCB S.A. Neurodegenerative Disorder Therapeutics Product Offered
11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 UCB S.A. Main Business Overview
11.6.5 UCB S.A. Latest Developments
11.7 F. Hoffmann- La Roche Ltd.
11.7.1 F. Hoffmann- La Roche Ltd. Company Information
11.7.2 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product Offered
11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 F. Hoffmann- La Roche Ltd. Main Business Overview
11.7.5 F. Hoffmann- La Roche Ltd. Latest Developments
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Information
11.8.2 H. Lundbeck Neurodegenerative Disorder Therapeutics Product Offered
11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 H. Lundbeck Main Business Overview
11.8.5 H. Lundbeck Latest Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Information
11.9.2 Merck KGaA Neurodegenerative Disorder Therapeutics Product Offered
11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Merck KGaA Main Business Overview
11.9.5 Merck KGaA Latest Developments
11.10 GlaxoSmithKline PLC
11.10.1 GlaxoSmithKline PLC Company Information
11.10.2 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Offered
11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 GlaxoSmithKline PLC Main Business Overview
11.10.5 GlaxoSmithKline PLC Latest Developments
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Information
11.11.2 AbbVie Inc. Neurodegenerative Disorder Therapeutics Product Offered
11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 AbbVie Inc. Main Business Overview
11.11.5 AbbVie Inc. Latest Developments
11.12 Bristol Myers Squibb Company
11.12.1 Bristol Myers Squibb Company Company Information
11.12.2 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Offered
11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Bristol Myers Squibb Company Main Business Overview
11.12.5 Bristol Myers Squibb Company Latest Developments
11.13 Boehringer Ingeiheim International GmbH
11.13.1 Boehringer Ingeiheim International GmbH Company Information
11.13.2 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Offered
11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Boehringer Ingeiheim International GmbH Main Business Overview
11.13.5 Boehringer Ingeiheim International GmbH Latest Developments
11.14 Bayer AG
11.14.1 Bayer AG Company Information
11.14.2 Bayer AG Neurodegenerative Disorder Therapeutics Product Offered
11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Bayer AG Main Business Overview
11.14.5 Bayer AG Latest Developments
11.15 Eisai Co., Ltd
11.15.1 Eisai Co., Ltd Company Information
11.15.2 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product Offered
11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Eisai Co., Ltd Main Business Overview
11.15.5 Eisai Co., Ltd Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂